Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083603 · ClinicalTrials.gov registry record · Phase 1
Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
NCT00083603 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 150 participants.
The verdict
NCT00083603, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of and immune response to two HIV vaccine formulations, rMVA-HIV and rFPV-HIV, alone and in combination, in HIV uninfected adults.
Interventions
- BIOLOGICAL rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)
- BIOLOGICAL rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)
- BIOLOGICAL Empty TBC-FPV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083603
The ClinicalTrials.gov registry entry for NCT00083603 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT) is the first listed.
NCT00083603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083603 about?
NCT00083603 is a clinical study titled "Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults". The purpose of this study is to evaluate the safety of and immune response to two HIV vaccine formulations, rMVA-HIV and rFPV-HIV, alone and in combination, in HIV uninfected adults.
What is the current status of trial NCT00083603?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2004-09. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00083603?
The interventions under investigation include: rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT) (BIOLOGICAL), rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT) (BIOLOGICAL), Empty TBC-FPV (BIOLOGICAL).
Who is sponsoring clinical trial NCT00083603?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.